199
Participants
Start Date
October 5, 2022
Primary Completion Date
April 3, 2025
Study Completion Date
April 16, 2025
GV1001 Placebo
0.9% normal saline
GV1001 0.56mg
Lyophilized peptide from hTERT
GV1001 1.12mg
Lyophilized peptide from hTERT
Casa di Cura iGEA SpA c/o Casa di Cura Privata del Policlinico, Milan
Hospital Universitario Quirónsalud Madrid, Pozuelo de Alarcón
Flourish Research - Alzheimer's Memory Center/AMC Research, LLC, Charlotte
Accel Research Sites (ARS) - NeuroStudies, Decatur
Hôpital La Grave, Toulouse
Outpatient Psy Care, Miami
Finlay Medical Research Corporation - Miami Dade, Miami
First Choice Neurology - Aventura Neurologic Associates, Adventura
Palm Beach Neurology and Premiere Research Institute, West Palm Beach
Palm Beach Neurological Center, Palm Beach Gardens
Finlay Medical Research Corporation - Greenacres, Greenacres City
Neurostudies - Port Charlotte, Port Charlotte
Aqualane Clinical Research, Naples
Neurology Clinic - Cordova, Cordova
Hospital Victoria Eugenia, Seville
Hospital Universitario Virgen del Rocío, Seville
Hospital Universitari i Politècnic La Fe, Valencia
Hôpital Pierre Wertheimer, Bron
Terveystalo Oulu, Oulu
Global Medical Institutes - Princeton Medical Institute, Princeton
Brain Research Center - Amsterdam, Amsterdam
Brain Research Center - Zwolle, Zwolle
Brain Research Centre - Den Bosch, Amsterdam
Fundacio ACE, Barcelona
Centrum Medyczne Neuromed - Ośrodek Badań Klinicznych, Bydgoszcz
Wroctawskie Centrum Alzheimerowskie (WCA), Wroclaw
Galen Clinic, Lublin
Centrum Medyczne Neuroprotect, Warsaw
Niepubliczny Zakład Opieki Zdrowotnej NOVO-MED, Katowice
Clinhouse Centrum Medyczne, Zabrze
Unidade Local de Saúde de Santa Maria, E. P. E. - Hospital de Santa Maria, Lisbon
Hospital Pedro Hispano, Senhora da Hora
Unidade Local de Saúde de Braga, E. P. E (Hospital de Braga), Braga
Hospital Universitari Vall d'Hebrón, Barcelona
Hospital Clinic de Barcelona, Barcelona
Lead Sponsor
GemVax & Kael
INDUSTRY